Psychological impact and quality of life in pediatric patients with chronic skin disorders: a systematic review (2010–2025) - Top-Institutions - MDSpire

Psychological impact and quality of life in pediatric patients with chronic skin disorders: a systematic review (2010–2025)

  • By

  • Abdulaziz Fahd AlKaabba

  • Shahd Muhammed Aldosari

  • Taif Abdullah Alwadai

  • Aldana Abdulrahaman Alodayani

  • Duna Saad Alhumaidan

  • Wajed Shuliweeh Alenezi

  • Renad Sami Almuharib

  • Renad Abdullah Almosa

  • July 3, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago
    Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago

    Chicago, Illinois

    Key Differentiators

    • Pediatric Dermatology

  • #2

    Icahn School of Medicine at Mount Sinai / Mount Sinai Health System
    Icahn School of Medicine at Mount Sinai / Mount Sinai Health System

    New York, New York

    Key Differentiators

    • Dermatology

Original Source(s)

Psychological impact and quality of life in pediatric patients with chronic skin disorders: a systematic review (2010–2025)

  • by Abdulaziz Fahd AlKaabba, Shahd Muhammed Aldosari, Taif Abdullah Alwadai, Aldana Abdulrahaman Alodayani, Duna Saad Alhumaidan, Wajed Shuliweeh Alenezi, Renad Sami Almuharib, Renad Abdullah Almosa

  • July 3, 2026

Related Content

Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists